A91 Abstracts (71.2%) followed by cost of hospital stay (21.8%) and diagnostic costs (7%). Costs of hospital care for patients with ventricular arrhythmias were significantly higher as compared to patients with heart failure (€5890. 82 and €1959.35, respectively). CONCLUSIONS: This study demonstrates that ARVC is associated with high hospitalization costs in Poland, mainly due to large costs of antiarrhythmic procedures. OBJECTIVES: To investigate different scenarios of warfarin treatment for patients with non-valvular atrial fibrillation who are eligible to receive anticoagulation for stroke prevention. Scenarios include different proportions of eligible patients being treated, as well as the level of anticoagulation obtained (i.e. within and outside the recommended INR range).
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DRIVERS OF UNDERUSE OF VITAMIN K ANTAGONISTS IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION IN FRANCE: THE ENSEFAL STUDY
Guenoun M 1 , Le Jeunne P 2 , Lamarque H 3 1 Clinique Bouchard, Marseille, France; 2 BKL-Thales, Boulogne Billancourt, France; 3 AstraZeneca France, Rueil-Malmaison, France OBJECTIVES: Describe prevalence and characteristics of patients with chronic nonvalvular atrial fibrillation (NVAF) and ≥1 risk factor (RF) for thromboembolism in France in 2004, and document reasons for vitamin K antagonists (VKA) underuse in those patients for whom anticoagulation is indicated. METHODS: Cross sectional study. All patients with arrhythmia or AF presenting to cardiologists (n = 43) from the THALES observatory during a 3-month period were evaluated via ques-tionnaire. Statistical comparisons were by chi 2 and ANOVA analyses. Data were extrapolated using the THALES database to give representative national values. RESULTS: 409 patients met the inclusion criteria, i.e., confirmed NVAF and ≥1 thromboembolic RF (mean age 76 years; mean number of thromboembolic RF 2.11; 58.7% male). Of these, 37.2% had 1 RF, 28.9% had 2 RF and 34.0% had ≥3 RF. VKA was prescribed to 65.5% of patients. VKA treatment was associated with a higher mean number of RF (2.28) than aspirin (2.20) or no treatment (1.61). Among VKA-treated patients, 18.6% were judged difficult to stabilise/not stabilised by the physician. Main reasons for not prescribing VKA were insufficient risk: benefit (37.6%), patient's refusal due to VKA restrictions (23.4%) and patient's inherent haemorrhagic risk (19.1%). According to anticoagulation exclusion criteria (severe hepatic insufficiency, recent stroke, and patient's inherent haemorrhagic risk) most patients not treated with VKA (77.3%) would have been eligible for anticoagulation. Extrapolation of these findings to the French population equated to 426,731 (95% CI 420,099-433,363) patients with chronic NVAF. Of these, 147,124 (34.5%) would not be treated with VKA, even though 113,719 would have been eligible for anticoagulation. CONCLUSIONS: These data suggest that one third of French patients with chronic NVAF and ≥1 thromboembolic RF presenting to cardiologists are currently not treated with VKA. Main drivers for this non-prescription are more related to risk and constraints of VKA treatment than formal contraindications.
PCV11 ANTICOAGULATION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: AN EVALUATION OF STABILITY AND EARLY FACTORS THAT PREDICT LONGER-TERM STABILITY ON WARFARIN IN A LARGE UK POPULATION
Currie CJ 1 , McEwan P 2 , Emmas C 3 , Peters JR 4 1 Cardiff University, Cardiff, UK; 2 Cardiff University, Cardiff, Wales, UK; 3 AstraZeneca-UK, Luton, Bedfordshire, UK; 4 University Hospital of Wales, Cardiff, UK OBJECTIVES: To determine the proportion of patients with non-valvular atrial fibrillation (NVAF) treated with warfarin that achieved INR stability. To then evaluate the associations between stability and outcome, and factors that predict stability. METHODS: A retrospective record linkage study in 1513 patients with NVAF treated with warfarin for a minimum of six months. The setting was a large UK population (ª450,000 people). The main outcome measures were stability defined as six consecutive months within the target INR range (2.0-3.0), thromboembolic and bleeding event rates, and mortality. Secondary outcome measures included the predictive value of baseline characteristics and other treatment variables. RESULTS: Stability was achieved in 52% of the study group. Standardised mean survival was significantly higher in the group who achieved stability (D = 16.9 months, p < 0.001) with a hazard ratio of 4.36 (p < 0.001). The stable group had a lower rate of both thromboembolic events (0.8% vs. 2.3% per patient year) and major bleeds (0.4% vs. 1.2% per patient year). Failure to achieve stability was associated with age (odds ratio 1.01 (95% CI 1.001-1.021)) and morbidity at baseline (OR 1.015; 95% CI 1.007-1.022). Greater variability in INR was also associated with a failure to achieve stability (OR 1.518; 95% CI 1.427-1.615). Receiver operator characteristic (ROC) analysis using data from the first three month of treatment demonstrated good discrimination of stability using age and morbidity at baseline and percent time in range and frequency of visits during first three months treatment (AUC 0.780; SE 0.012; 95% CI 0.757-0.803). CONCLUSIONS: Many patients never achieved
